Vivanza Biosciences Limited
BSE: VIVANZA · Pharmaceuticals · sector
₹1.43BSE close 2026-10-26
Key numbers
Market cap₹6 cr
Price₹1.43
52w high / low₹3 / ₹1
P/E4.2xSector median 27.9x
P/B1.3xSector median 2.9x
Book value₹1.1
Dividend yield–Sector median 0.48%
ROE10.9%Sector median 11.7%
ROCE6.5%Sector median 12.3%
OPM0.4%Sector median 14.0%
Debt / equity2.34xSector median 0.16x
EV/EBITDA31.7xSector median 18.6x
Interest cover3.1x
Current ratio1.13x
Sales growth 3y+101.3%Sector median +9.6%
Profit growth 3y-11.6%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹0 cr vs borrowings ₹10 cr (FY26): borrowings are higher by ₹10 cr.
- Operating profit covered interest 3.1x in the last 12 months.
- Net loss in 2 of the last 6 quarters.
- Other income was 104% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹1.43 on 2026-10-26: -47.4% from the 52-week high, +1.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹4.26 · low ₹1.43
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 9 | 55 | 45 | 6 | 9 |
| EBITDA | -1 | 0 | 1 | 0 | -0 | -0 |
| OPM % | -197.9% | 1.7% | 1.1% | 0.5% | -3.6% | -0.9% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -1 | 0 | 1 | 0 | -0 | 0 |
| EPS (₹) | 0.25 | 0.02 | 0.14 | 0.05 | 0.11 | 0.04 |
| Revenue YoY | +1,225.0% | +3.9% | ||||
| Profit YoY | – | +66.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 9 | 14 | 14 | 7 | 116 | 116 |
| EBITDA | 0 | 1 | 1 | -0 | 1 | 0 |
| Net profit | 0 | 1 | 0 | -1 | 0 | 0 |
| EPS (₹) | 1.16 | 1.42 | 0.08 | 0.17 | 0.10 | 0.34 |
| Revenue growth | +55.3% | +1.4% | -48.5% | +1,462.1% | – | |
| Profit growth | +23.9% | -43.9% | -309.4% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +101.3% | – | – |
| Net profit | -11.6% | – | – |
| EPS | -58.7% | – | – |
| Share price | – | -32.6% (2y) | -24.9% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 4 | 4 |
| Borrowings | 9 | 10 |
| Cash & equivalents | 0 | 0 |
| Total assets | 16 | 22 |
| Fixed assets | 1 | 1 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 8 | 12 |
| Inventory | 2 | 4 |
| Payables | 3 | 7 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -2 | -1 |
| Cash from investing | -0 | -0 |
| Cash from financing | 2 | 1 |
| Capex | 0 | 0 |
| Free cash flow | -3 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -17.0% | 9.0% |
| ROCE % | -2.5% | 5.7% |
| Debtor days | 396 | 39 |
| Inventory days | 121 | 11 |
| Payable days | 140 | 23 |
| Cash conversion cycle (days) | 377 | 27 |
| Working capital days | 159 | 7 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| VIVANZA | ₹6 cr | 4.2x | 1.3x | 10.9% | 6.5% | 0.4% | +101.3% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | VIVANZA |
| BSE code | 530057 |
| ISIN | INE984E01035 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.